Interim Dermagraft foot ulcer data fail to show significant benefits in all patients
This article was originally published in Clinica
Interim results of a new clinical trial of Dermagraft for treating diabetic foot ulcers have shown that although the skin substitute healed more ulcers than the control treatment, the improvement was not statistically significant.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.